Principal Financial Group Inc Puma Biotechnology, Inc. Transaction History

Principal Financial Group Inc

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$1.64 - $3.3 $54,912 - $110,493	-33,483 Closed	0 $0
Q1 2022 May 09, 2022	SELL	$2.13 - $3.24 $36,129 - $54,956	-16,962 Reduced 33.62%	33,483 $96,000
Q4 2021 Feb 09, 2022	BUY	$2.85 - $6.58 $16,766 - $38,710	5,883 Added 13.2%	50,445 $153,000
Q3 2021 Nov 09, 2021	SELL	$6.63 - $9.39 $2,201 - $3,117	-332 Reduced 0.74%	44,562 $312,000
Q2 2021 Aug 10, 2021	SELL	$8.98 - $11.6 $402,205 - $519,552	-44,789 Reduced 49.94%	44,894 $412,000
Q1 2021 May 10, 2021	BUY	$9.38 - $13.63 $63,737 - $92,615	6,795 Added 8.2%	89,683 $872,000
Q4 2020 Feb 08, 2021	SELL	$7.78 - $12.13 $240,518 - $374,998	-30,915 Reduced 27.17%	82,888 $850,000
Q3 2020 Nov 06, 2020	BUY	$9.5 - $11.14 $471,855 - $553,312	49,669 Added 77.45%	113,803 $1.15 Million
Q2 2020 Aug 05, 2020	BUY	$7.01 - $13.24 $449,579 - $849,134	64,134 New	64,134 $669,000
Q2 2019 Aug 12, 2019	SELL	$12.3 - $35.76 $73,369 - $213,308	-5,965 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$20.77 - $42.37 $123,893 - $252,737	5,965 New	5,965 $231,000
Q4 2018 Feb 14, 2019	SELL	$20.07 - $46.7 $228,276 - $531,165	-11,374 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$41.2 - $59.85 $62,624 - $90,972	1,520 Added 15.43%	11,374 $522,000
Q2 2018 Aug 13, 2018	BUY	$48.3 - $68.25 $2,801 - $3,958	58 Added 0.59%	9,854 $0
Q1 2018 May 14, 2018	SELL	$59.7 - $99.25 $298 - $496	-5 Reduced 0.05%	9,796 $666,000
Q4 2017 Feb 13, 2018	BUY	$93.85 - $132.45 $501,534 - $707,812	5,344 Added 119.9%	9,801 $969,000
Q3 2017 Nov 02, 2017	BUY	$72.0 - $119.75 $320,904 - $533,725	4,457	4,457 $534,000

101

29M

50.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $125M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.